To examine the relation between NLR (neutrophil–lymphocyte ratio) and PLR (platelet–lymphocyte ratio) rates and the severity of ED (erectile dysfunction) and the effect of tadalafil 5 mg/day on these, a total of 143 patients were retrospectively evaluated. Sixty‐three patients with ED who came for follow‐up examinations in the 1st month of the treatment were included as the study group, and 80 men who were not diagnosed with ED were as the control group. The age and Charlson Comorbidity Indexes (CCI) of the study and control groups were compared with the IIEF 5, NLR and PLR values before and after the treatment. The mean age and median CCI were higher in the severe ED group (p < 0.05). The mean NLR and PLR values were lower in the control group (p < 0.001). In the study group, the NLR and PLR values decreased with the increase in the IIEF 5 scores (p < 0.001). The ROC curve was significant for the NLR and PLR scores (AUC = 0.779, [95% CI: 0.698–0.860]; AUC = 0.754, [95% CI: 0.670–0.838] p < 0.001). Although more prospective and randomized studies are needed, the systemic inflammation decreases and the clinical symptoms improve in patients who use tadalafil 5 mg/day.
<b><i>Introduction:</i></b> Numerous factors such as endothelial disease and hormonal disorder cause the development of erectile dysfunction (ED). However, the relationship between vitamin D deficiency (VDD) and ED is unclear. Moreover, the benefit of vitamin D replacement on ED patients with VDD is uncertain. As far as we know, there is no study yet in the literature regarding the addition of vitamin D to phosphodiesterase type 5 inhibitors in the treatment of ED patients with VDD. In this study, we investigated whether adding vitamin D to daily tadalafil treatment would be beneficial in ED patients with VDD. <b><i>Methods:</i></b> A total of 111 patients with VDD accompanying ED were retrospectively evaluated between January 2016 and December 2019. Patients were divided into 2 groups according to the treatment they received. Group 1 (<i>n</i> = 58) was treated with daily oral tadalafil 5 mg, while group 2 (<i>n</i> = 53) received oral tadalafil 5 mg and 4,000 IU vitamin D3. Total International Index of Erectile Function-15 (IIEF-15) scores and vitamin D levels of the groups were compared at the end of the study. <b><i>Results:</i></b> The mean vitamin D level was increased statistically significant in group 2, but no difference was seen in group 1 (<i>p</i> < 0.001 and <i>p</i> > 0.05, respectively). There was a significant increase in median erectile function, orgasmic function, sexual desire, sexual satisfaction, and overall satisfaction scores in both groups (<i>p</i> < 0.001). However, the increase in median erectile function and sexual desire scores was significantly higher in group 2 compared to group 1 at the end of the study (<i>p</i> = 0.01 and <i>p</i> < 0.001, respectively). <b><i>Conclusion:</i></b> We found that adding vitamin D to 5 mg oral daily tadalafil treatment may have an additional positive effect on erectile function and sexual desire in ED patients with VDD.
Purpose
To evaluate pelvic floor and sexual dysfunction, and anxiety and depression symptoms in females with different urinary incontinence (UI) types.
Materials and Methods
A cross sectional evaluation was made of 73 patients diagnosed with UI in the Urology Clinic between December 2021 and November 2022. In addition to demographic data, the points were recorded from the International Consultation on Incontinence Questionnaire Female Lower Urinary Tract Symptoms (ICIQ‐FLUTS), Hospital Anxiety and Depression Scale (HADS), Female Sexual Function Index (FSFI), and the Pelvic Floor Distress Inventory‐20 (PFDI‐20).
Results
The mean age of the patients was 38.3 ± 3.7 years. Incontinence types of the patients were determined as 42% urgency urinary incontinence (UUI), 30.1% stress urgency incontinence (SUI), and 27.4% mixed type urinary incontinence (MUI). Anxiety symptoms were determined in 20.5% and depression symptoms in 41.1% of all the patients. The median ICIQ‐FLUTS score was determined to be significantly higher in the MUI patients than in the other types [25.5 (MUI) vs. 17 (SUI), p = 0.007; 16 (UUI), p = 0.001]. The median FSFI and HADS scores were seen to be similar in all the UI types (p = 0.1). The median PFDI‐20 score was found to be higher in the MUI group than in the UUI group (126.5 vs. 88.5, p = 0.02).
Conclusion
The sexual dysfunction and psychological symptoms were found to be similar in the patients according to UI type. The MUI patients were seen to have more incontinence symptoms compared to the other types and experienced more pelvic floor dysfunction than patients with UUI.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.